Diseases of the central nervous system continue to catalyse dealmaking as companies search for new therapies to tackle some major unmet medical needs.
Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty electrical activity in the brain.
Voyager Therapeutics is unlocking the potential of adeno-associated virus gene therapy to treat a range of neurological disorders, broadening the therapeutic window while ensuring efficacy and safety.
Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms with demonstrated profound efficacy (onset duration and/or prolonged treatment duration) in humans for the treatment of mental health disorders.
PsychoGenics uses a high-throughput platform comprising cameras and AI to analyze the behaviors of mice given a drug candidate before comparing them to a reference database. The platform enables the development of novel neuropsychiatric drugs and accelerates drug discovery.